Activity Assay:
Article Title: Tiotropium versus placebo for chronic obstructive pulmonary disease
Article Snippet: .. During the treatment period, patients were not allowed to use beta‐blockers, cromolyns, antileukotrienes, inhaled LABAs, long‐acting anticholinergics, or any other investigational drug Outcomes Primary : difference in daily physical activity measured in vector magnitude units (VMUs) by the triaxial Stayhealthy RT3 accelerometer at the end of the treatment period Secondary : the difference in physical activity measured in VMUs by the triaxial Stayhealthy RT3 accelerometer at 1 month and 2 month treatment period, trough (10±3 minutes predose) FEV 1 , peak FEV 1 as measured by the maximum post‐bronchodilator value obtained within 2 hours of testing on study days (30±5, 60±10, and 120±10 minutes), trough and peak SVC measured at the same time as the FEV 1 on each study day, trough and peak inspiratory capacity (IC) measured at the same time as the FEV 1 on each study day, trough and peak forced inspiratory volume in one second (FIV 1 ) measured at the same time as the FEV 1 on each study day, distance covered in the six‐minute walk distance (6MWD), modified Borg Dyspnoea Scale, quality of life as measured by the Chronic Respiratory Questionnaire (CRQ), use of salbutamol (rescue medication) during the treatment period, time point at which a 20% improvement from baseline in physical activity was achieved, physician’s Global Assessment Notes Funding : Boehringer Ingelheim Study number : Boehringer Ingelheim 205.269, ClinicalTrials.gov NCT00144326 Definitions : an exacerbation of COPD was defined as a complex of respiratory symptoms (two or more) COPD‐related (increased or new onset) with a duration of at least three days. ..
Article Title: Tiotropium versus placebo for chronic obstructive pulmonary disease
Article Snippet: .. Outcomes , Primary : difference in daily physical activity measured in vector magnitude units (VMUs) by the triaxial Stayhealthy RT3 accelerometer at the end of the treatment period Secondary : the difference in physical activity measured in VMUs by the triaxial Stayhealthy RT3 accelerometer at 1 month and 2 month treatment period, trough (10±3 minutes predose) FEV 1 , peak FEV 1 as measured by the maximum post‐bronchodilator value obtained within 2 hours of testing on study days (30±5, 60±10, and 120±10 minutes), trough and peak SVC measured at the same time as the FEV 1 on each study day, trough and peak inspiratory capacity (IC) measured at the same time as the FEV 1 on each study day, trough and peak forced inspiratory volume in one second (FIV 1 ) measured at the same time as the FEV 1 on each study day, distance covered in the six‐minute walk distance (6MWD), modified Borg Dyspnoea Scale, quality of life as measured by the Chronic Respiratory Questionnaire (CRQ), use of salbutamol (rescue medication) during the treatment period, time point at which a 20% improvement from baseline in physical activity was achieved, physician’s Global Assessment , . .. Notes , Funding : Boehringer Ingelheim Study number : Boehringer Ingelheim 205.269, ClinicalTrials.gov NCT00144326 Definitions : an exacerbation of COPD was defined as a complex of respiratory symptoms (two or more) COPD‐related (increased or new onset) with a duration of at least three days. COPD‐related respiratory symptoms consisted of cough, wheeze, dyspnoea, shortness of breath, chest tightness, or increase in production and/or purulence in sputum. These symptoms must have been accompanied with antibiotic treatment and/or systemic corticoids (oral, intramuscular or endovenous) or with a significant change in respiratory medication prescribed , .
Modification:Article Title: Tiotropium versus placebo for chronic obstructive pulmonary disease
Article Snippet: .. During the treatment period, patients were not allowed to use beta‐blockers, cromolyns, antileukotrienes, inhaled LABAs, long‐acting anticholinergics, or any other investigational drug Outcomes Primary : difference in daily physical activity measured in vector magnitude units (VMUs) by the triaxial Stayhealthy RT3 accelerometer at the end of the treatment period Secondary : the difference in physical activity measured in VMUs by the triaxial Stayhealthy RT3 accelerometer at 1 month and 2 month treatment period, trough (10±3 minutes predose) FEV 1 , peak FEV 1 as measured by the maximum post‐bronchodilator value obtained within 2 hours of testing on study days (30±5, 60±10, and 120±10 minutes), trough and peak SVC measured at the same time as the FEV 1 on each study day, trough and peak inspiratory capacity (IC) measured at the same time as the FEV 1 on each study day, trough and peak forced inspiratory volume in one second (FIV 1 ) measured at the same time as the FEV 1 on each study day, distance covered in the six‐minute walk distance (6MWD), modified Borg Dyspnoea Scale, quality of life as measured by the Chronic Respiratory Questionnaire (CRQ), use of salbutamol (rescue medication) during the treatment period, time point at which a 20% improvement from baseline in physical activity was achieved, physician’s Global Assessment Notes Funding : Boehringer Ingelheim Study number : Boehringer Ingelheim 205.269, ClinicalTrials.gov NCT00144326 Definitions : an exacerbation of COPD was defined as a complex of respiratory symptoms (two or more) COPD‐related (increased or new onset) with a duration of at least three days. ..
Article Title: Tiotropium versus placebo for chronic obstructive pulmonary disease
Article Snippet: .. Outcomes , Primary : difference in daily physical activity measured in vector magnitude units (VMUs) by the triaxial Stayhealthy RT3 accelerometer at the end of the treatment period Secondary : the difference in physical activity measured in VMUs by the triaxial Stayhealthy RT3 accelerometer at 1 month and 2 month treatment period, trough (10±3 minutes predose) FEV 1 , peak FEV 1 as measured by the maximum post‐bronchodilator value obtained within 2 hours of testing on study days (30±5, 60±10, and 120±10 minutes), trough and peak SVC measured at the same time as the FEV 1 on each study day, trough and peak inspiratory capacity (IC) measured at the same time as the FEV 1 on each study day, trough and peak forced inspiratory volume in one second (FIV 1 ) measured at the same time as the FEV 1 on each study day, distance covered in the six‐minute walk distance (6MWD), modified Borg Dyspnoea Scale, quality of life as measured by the Chronic Respiratory Questionnaire (CRQ), use of salbutamol (rescue medication) during the treatment period, time point at which a 20% improvement from baseline in physical activity was achieved, physician’s Global Assessment , . .. Notes , Funding : Boehringer Ingelheim Study number : Boehringer Ingelheim 205.269, ClinicalTrials.gov NCT00144326 Definitions : an exacerbation of COPD was defined as a complex of respiratory symptoms (two or more) COPD‐related (increased or new onset) with a duration of at least three days. COPD‐related respiratory symptoms consisted of cough, wheeze, dyspnoea, shortness of breath, chest tightness, or increase in production and/or purulence in sputum. These symptoms must have been accompanied with antibiotic treatment and/or systemic corticoids (oral, intramuscular or endovenous) or with a significant change in respiratory medication prescribed , .
other:
|